Abstract:Background As one of the major cancers threatening human health, Breast Cancer (BC) has become the health concern of WHO (World Health Organization) all the year round. In recent years, new cases of BC have gradually increased, reaching 11.7% in 2020. In terms of treatment, the cell death is a basic way to treat cancer, and necroptosis is found to be a programmed form of necrotic cell death, which is related to cancer progression, metastasis and immune monitoring. In this study, the influence and role of Necroptosis-Related Genes (NRGs) in BC were analyzed, and the subtypes, prognostic model and subgroups were studied, respectively. Methods Four aspects were included in the research content. 1) Difference analysis. The Wilcoxon Test was applied to identify differences between normal people and BC patients. 2) Sub-type analysis. Based on Cox regression analysis, the key genes related to prognosis were extracted and applied to the Consensus clustering technology. Subsequently, after obtaining the subtypes, the Wilcoxon Test was applied to extract the differential genes of subtypes. 3) Prognostic analysis. Further, according to the survival time and state of patients, the genes related to the severity of the disease were extracted by the Cox regression, and the classification modeling of high risk and low risk was carried out by Lasso. 4) Sub-group analysis. Combined with the high- and low-risk labels of patients, the composition of differential genes was further analyzed. Subsequently, GO, KEGG, and ssGSEA analyses were performed separately. Results 1) There are differences in gene expression between normal and BC patients. The results showed that, PLK1, CDKN2A, and TERT were significantly different genes with |LogFC| > 2. In addition, PPI (Protein to Protein Interaction) demonstrated that CASP8, TRAF2, TNFRSF1A, HSP90AA1, CYLD, and FADD were hubs in the network. Moreover, coexpression relationship of these genes can be found in the correlation graph. 2) Unsupervised techniques suggested that there are 2 subtype characteristics in BC patients. The clustering results obtained the detailed clinical information of the 2 subtypes, and the survival analysis showed that different subtypes had different survival states. Similarly, the heat map also verified that these 2 types had different gene expression. 3) The validation demonstrated that the prognostic model has good effect. On the one hand, we found that 'BCL2', 'FLT3', and 'PLK1' were the main genes with different expression levels in high- and low-risk patients. On the other hand, not only the ROC, risk curve and survival curve were verified, but also the PCA distribution and forest plots were demonstrated. These results showed that our model has good prognostic effect. 4) There were some differences in immune scores between high- and low-risk groups. A total of 94 genes were differentially expressed in different groups. Immune cell analysis and pathway analysis showed that, in general, immune scores of low risk subgroup were higher than that in the high-risk subgroup. Conclusions Our findings revealed the crucial role of NRGs in BC. These are important for tumor immunity and can be used to predict the prognosis of BC.

Identification of a novel necroptosis-related classifier to predict prognosis and guide immunotherapy in breast invasive carcinoma

Identification of Necroptosis-Related Long Noncoding RNAs for Immunotherapy Selection and Prognosis Prediction in Patients with Colorectal Cancer

Identification of Necroptosis-Related Lncrnas for Prognosis Prediction and Screening of Potential Drugs in Patients with Colorectal Cancer

Identification and validation of a novel necroptosis-related molecular signature to evaluate prognosis and immune features in breast cancer

Identification and Validation of a Necroptosis-Related Prognostic Model in Tumor Recurrence and Tumor Immune Microenvironment in Breast Cancer Management

Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer

Development and Validation of a Robust Necroptosis Related Classifier for Colon Adenocarcinoma

Identification and Modeling of Necroptosis-Related Genes Associated with the Prognosis of Breast Cancer

Necroptosis‐related lncRNA to establish novel prognostic signature and predict the immunotherapy response in breast cancer

Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma

Prognostic Model Associated with Necroptosis in Colorectal Cancer based on Transcriptomic Analysis and Experimental Validation

Comprehensive Analysis of Necroptosis-Related Genes as Prognostic Factors and Immunological Biomarkers in Breast Cancer

A Novel Necroptosis-Related Gene Signature in Skin Cutaneous Melanoma Prognosis and Tumor Microenvironment

Analysis and Identification of the Necroptosis Landscape on Therapy and Prognosis in Bladder Cancer

Single‑cell RNA‑seq necroptosis‑related genes predict the prognosis of breast cancer and affect the differentiation of CD4+ T cells in tumor immune microenvironment.

Predicting the Clinical Outcome of Triple-Negative Breast Cancer Based on the Gene Expression Characteristics of Necroptosis and Different Molecular Subtypes

Pan-cancer analysis of necroptosis-related gene signature for the identification of prognosis and immune significance

Development and Validation of a Necroptosis-Related Gene Prognostic Score to Predict Prognosis and Efficiency of Immunotherapy in Gastric Cancer

Identification of Molecular Subtypes, Risk Signature, and Immune Landscape Mediated by Necroptosis-Related Genes in Non-Small Cell Lung Cancer.

A Novel Prognostic Predictor of Immune Microenvironment and Therapeutic Response in Kidney Renal Clear Cell Carcinoma based on Necroptosis-related Gene Signature

A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma